Pakistan Pharmas Call For 20 Percent Increase In Allowed Drug Prices
This article was originally published in PharmAsia News
The Pakistan Pharmaceutical Manufacturers Association is calling for a 20 percent increase in the allowed prices for drugs in the country. The industry cites added costs of raw materials and energy as well as the devalued Pakistani currency as reasons for allowing a price hike. The group said lifting the cap on drug prices was essential if the nation's drug-making industry is to survive. The PPMA estimated lifting the caps would save Pakistan the $3 billion cost of importing foreign-made drugs that comprise more than 90 percent of drugs available in the country. (Click here for more
You may also be interested in...
CDER wants sponsors to use the NextGen Portal for electronic submission of promotional pieces to the Office of Prescription Drug Promotion, rather than sending in paper or physical media such as CDs; availability of this alternative pathway does not affect requirement for eCTD submission of some types of promotional materials starting in June 2021.
US FDA research finds consumer attitudes are more positive when animated characters personify drug benefits or sufferers, rather than representing the disease itself; OPDP staff also present research on consumer understanding of oncology endpoints and prescribers’ ability to detect deceptive ads.
As generalist investors continue to push higher the stock prices of biotech companies that announce the most tenuous of coronavirus developments, the track record of biotech companies developing even vaccines for which the antigen is proven to be safe and efficacious remains poor.